Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
Foghorn Therapeutics Inc. (FHTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update - FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potenti
How this was made
The 30-second read
Why it matters
The disclosure updates clinical progress (FHD-909 Phase 1 on track), expands pipeline plans (IND targeted in 2027 for an immunology/inflammation asset), and flags a specific operational delay for CBPd-171, plus reiterates cash runway into 1H 2028.
Market read
Traders can update expectations for near-term clinical execution (Phase 1 dosing progress) and medium-term milestone calendars (IND targets), while monitoring the disclosed CRO-related delay.
What to watch
Cash runway is stated, but the filing does not quantify burn rate changes or probability-weighted milestone timing; traders may overreact to IND target years without updated cost or enrollment metrics.
Background
This is an SEC Form 8-K (Item 2.02) with an exhibit providing Foghorn’s second-quarter 2026 financial and corporate update alongside its 10-Q.
Ticker impact
Foghorn’s 8-K update says its FHD-909 Phase 1 dose escalation is on track and targets an IND for its immunology asset in 2027.
Bias modestly positive, with trading likely sensitive to any later updates on dose-escalation progress and the delayed CBPd-171 timeline.
The filing is a primary disclosure (8-K with exhibit) and includes specific program status, cash runway, and a concrete delay that can affect expectations for milestones.
Market effects
Biotech investors may reprice clinical-stage oncology and epigenetics-platform risk as milestone timing and cash runway are updated.
Limited, primarily affects US small-cap biotech sentiment.
Low; collaboration with Lilly is US-centric and no cross-border regulatory action is disclosed.
Counterpoint
The update is heavy on preclinical and planning language, and the only explicit negative is a timeline delay at a third-party CRO, which can signal broader execution risk.
Key entities
- companyFoghorn Therapeutics Inc.
Clinical-stage biotech providing a Q2 2026 financial and corporate update via 8-K, including pipeline milestones and cash runway.
- companyLilly
Collaboration partner for FHD-909 development under a 50/50 US co-development and co-commercialization agreement.
- programFHD-909 (LY4050784)
Oral SMARCA2 selective inhibitor in Phase 1 dose escalation for SMARCA4-mutant NSCLC, with combination plans with pembrolizumab pending Phase 1 results.
- programCBPd-171
Selective CBP degrader with a weekly LAI formulation; timeline delayed due to an unexpected operational issue at a third-party CRO.